{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Arm+B%3A+Normal+Saline",
    "query": {
      "intervention": "Arm B: Normal Saline"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 91,
    "total_pages": 10,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Arm+B%3A+Normal+Saline&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-22T20:59:20.195Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06375512",
      "title": "A Study to Describe the Safety, Reactogenicity, and Immunogenicity of Herpes Zoster IN001 mRNA Vaccine (IN001) in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Herpes Zoster"
      ],
      "interventions": [
        {
          "name": "HZ Vaccine (IN001)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Shingrix",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Shenzhen Shenxin Biotechnology Co., Ltd",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "69 Years",
        "sex": "ALL",
        "summary": "50 Years to 69 Years"
      },
      "enrollment_count": 150,
      "start_date": "2024-07-05",
      "completion_date": "2026-02-20",
      "has_results": false,
      "last_update_posted_date": "2026-03-31",
      "last_synced_at": "2026-09-22T20:59:20.195Z",
      "location_count": 1,
      "location_summary": "Hollywood, Florida",
      "locations": [
        {
          "city": "Hollywood",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06375512"
    },
    {
      "nct_id": "NCT00998946",
      "title": "Study of Pralatrexate to Treat Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lymphoma, B-Cell"
      ],
      "interventions": [
        {
          "name": "Pralatrexate",
          "type": "DRUG"
        },
        {
          "name": "Vitamin B12",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Folic Acid",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Spectrum Pharmaceuticals, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 29,
      "start_date": "2009-09",
      "completion_date": "2012-08",
      "has_results": true,
      "last_update_posted_date": "2021-11-05",
      "last_synced_at": "2026-09-22T20:59:20.195Z",
      "location_count": 11,
      "location_summary": "Beverly Hills, California • Post Falls, Idaho • Chicago, Illinois + 8 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Post Falls",
          "state": "Idaho"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Shreveport",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00998946"
    },
    {
      "nct_id": "NCT02435069",
      "title": "A Within Subjects Comparison of Two Antegrade Flushing Regimens in Children",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Fecal Incontinence",
        "Neurogenic Bowel"
      ],
      "interventions": [
        {
          "name": "Dose Response - NS and USP Glycerin - First Intervention",
          "type": "DRUG"
        },
        {
          "name": "Effectiveness - NS and USP Glycerin - Second Intervention",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Nemours Children's Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "12 Years",
        "sex": "ALL",
        "summary": "3 Years to 12 Years"
      },
      "enrollment_count": 5,
      "start_date": "2016-02-09",
      "completion_date": "2018-03-30",
      "has_results": true,
      "last_update_posted_date": "2019-08-28",
      "last_synced_at": "2026-09-22T20:59:20.195Z",
      "location_count": 1,
      "location_summary": "Jacksonville, Florida",
      "locations": [
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02435069"
    },
    {
      "nct_id": "NCT05375838",
      "title": "A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1073 (COVID-19/Influenza) Vaccine in Adults 18 to 75 Years Old",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "SARS-CoV-2",
        "Influenza"
      ],
      "interventions": [
        {
          "name": "mRNA-1073",
          "type": "BIOLOGICAL"
        },
        {
          "name": "mRNA-1010",
          "type": "BIOLOGICAL"
        },
        {
          "name": "mRNA-1273",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "ModernaTX, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 550,
      "start_date": "2022-05-13",
      "completion_date": "2022-12-29",
      "has_results": true,
      "last_update_posted_date": "2024-02-28",
      "last_synced_at": "2026-09-22T20:59:20.195Z",
      "location_count": 14,
      "location_summary": "Hollywood, Florida • Peoria, Illinois • Sioux City, Iowa + 9 more",
      "locations": [
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "Peoria",
          "state": "Illinois"
        },
        {
          "city": "Sioux City",
          "state": "Iowa"
        },
        {
          "city": "Metairie",
          "state": "Louisiana"
        },
        {
          "city": "Norfolk",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05375838"
    },
    {
      "nct_id": "NCT01783821",
      "title": "LIPS-B: Lung Injury Prevention Study With Budesonide and Beta",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Respiratory Distress Syndrome (ARDS)"
      ],
      "interventions": [
        {
          "name": "Budesonide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Formoterol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 61,
      "start_date": "2013-07",
      "completion_date": "2015-12",
      "has_results": true,
      "last_update_posted_date": "2016-09-05",
      "last_synced_at": "2026-09-22T20:59:20.195Z",
      "location_count": 5,
      "location_summary": "Tucson, Arizona • Stanford, California • Jacksonville, Florida + 2 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01783821"
    },
    {
      "nct_id": "NCT03840122",
      "title": "ACB + IPACK Block With or Without Local Infiltration in RA-TKA",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Knee Arthropathy"
      ],
      "interventions": [
        {
          "name": "ACB + IPACK block with injection of local anesthetic",
          "type": "OTHER"
        },
        {
          "name": "ACB + IPACK block without injection",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of Louisville",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2019-10-08",
      "completion_date": "2019-10-08",
      "has_results": false,
      "last_update_posted_date": "2019-10-10",
      "last_synced_at": "2026-09-22T20:59:20.195Z",
      "location_count": 1,
      "location_summary": "Louisville, Kentucky",
      "locations": [
        {
          "city": "Louisville",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03840122"
    },
    {
      "nct_id": "NCT04616586",
      "title": "SILtuximab in Viral ARds (SILVAR) Study",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Acute Respiratory Distress Syndrome",
        "Lung Diseases",
        "Pneumonia",
        "Respiratory Tract Infections",
        "Respiratory Tract Disease"
      ],
      "interventions": [
        {
          "name": "Siltuximab",
          "type": "DRUG"
        },
        {
          "name": "Normal Saline",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "RECORDATI GROUP",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "12 Years to 65 Years"
      },
      "enrollment_count": 555,
      "start_date": "2020-11-13",
      "completion_date": "2021-04-01",
      "has_results": false,
      "last_update_posted_date": "2021-04-19",
      "last_synced_at": "2026-09-22T20:59:20.195Z",
      "location_count": 2,
      "location_summary": "Lansing, Michigan • Charlotte, North Carolina",
      "locations": [
        {
          "city": "Lansing",
          "state": "Michigan"
        },
        {
          "city": "Charlotte",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04616586"
    },
    {
      "nct_id": "NCT06896136",
      "title": "Study in Healthy Adults Challenged With Enterotoxigenic E. Coli, of the Safety, Tolerability and Anti-Diarrheal Activity of VENBETA6890, an Orally Administered, Human Monoclonal IgA",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Diarrhea Infectious"
      ],
      "interventions": [
        {
          "name": "VENBETA6890",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mark Klempner",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 36,
      "start_date": "2025-02-11",
      "completion_date": "2025-05-22",
      "has_results": false,
      "last_update_posted_date": "2025-07-22",
      "last_synced_at": "2026-09-22T20:59:20.195Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06896136"
    },
    {
      "nct_id": "NCT02287467",
      "title": "Evaluating the Safety and Efficacy of Anti-Influenza Intravenous Hyperimmune Immunoglobulin (IVIG) in Adults Hospitalized With Influenza",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Influenza A",
        "Influenza B"
      ],
      "interventions": [
        {
          "name": "Intravenous hyperimmune immunoglobulin (IVIG)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo for IVIG",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 329,
      "start_date": "2015-01",
      "completion_date": "2018-06-07",
      "has_results": true,
      "last_update_posted_date": "2019-11-14",
      "last_synced_at": "2026-09-22T20:59:20.195Z",
      "location_count": 17,
      "location_summary": "San Diego, California • Denver, Colorado • Chicago, Illinois + 14 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02287467"
    },
    {
      "nct_id": "NCT07145164",
      "title": "Interleukin-15 to Promote Post-ART Control of HIV",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HIV"
      ],
      "interventions": [
        {
          "name": "N-803",
          "type": "DRUG"
        },
        {
          "name": "Saline placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Michael Peluso, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 20,
      "start_date": "2025-08-19",
      "completion_date": "2028-12",
      "has_results": false,
      "last_update_posted_date": "2026-01-22",
      "last_synced_at": "2026-09-22T20:59:20.195Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07145164"
    }
  ]
}